Benefit profile of anticoagulant therapy in sepsis: a nationwide multicentre registry in Japan

Kazuma Yamakawa1,2*, Yutaka Umemura2, Mineji Hayakawa3, Daisuke Kudo4, Masamitsu Sanui5, Hiroki Takahashi2, Yoshiaki Yoshikawa1, Toshimitsu Hamasaki6, Satoshi Fujimi1 and for the Japan Septic Disseminated Intravascular Coagulation (J-Septic DIC) study group

Abstract

Background: Little evidence supports anticoagulant therapy as effective adjuvant therapy to reduce mortality overall in sepsis. However, several studies suggest that anticoagulant therapy may reduce mortality in specific patients. This study aimed to identify a subset of patients with high benefit profiles for anticoagulant therapy against sepsis.

Methods: This post hoc subgroup analysis of a nationwide multicentre retrospective registry was conducted in 42 intensive care units in Japan. Consecutive adult patients with sepsis were included. Treatment effects of anticoagulants, e.g. antithrombin, recombinant thrombomodulin, heparin, and protease inhibitors, were evaluated by stratifying patients according to disseminated intravascular coagulation (DIC) and Sequential Organ Failure Assessment (SOFA) score. Intervention effects of anticoagulant therapy on in-hospital mortality and bleeding complications were analysed using Cox regression analysis stratified by propensity scores.

Results: Participants comprised 2663 consecutive patients with sepsis; 1247 patients received anticoagulants and 1416 received none. After adjustment for imbalances, anticoagulant administration was significantly associated with reduced mortality only in subsets of patients diagnosed with DIC, whereas similar mortality rates were observed in non-DIC subsets with anticoagulant therapy. Favourable associations between anticoagulant therapy and mortality were observed only in the high-risk subset (SOFA score 13–17; adjusted hazard ratio 0.601; 95% confidence interval 0.451, 0.800) but not in the subsets of patients with sepsis with low to moderate risk. Although the differences were not statistically significant, there was a consistent tendency towards an increase in bleeding-related transfusions in all SOFA score subsets.

Conclusions: The analysis of this large database indicates anticoagulant therapy may be associated with a survival benefit in patients with sepsis-induced coagulopathy and/or very severe disease.

Trial registration: University Hospital Medical Information Network Clinical Trial Registry (UMIN-CTR ID: UMIN000012543). Registered on 10 December 2013.

Keywords: Anticoagulants, Sepsis, Retrospective studies, Subgroup analysis, Disseminated intravascular coagulation, DIC
Background
Sepsis invariably leads to haemostatic abnormalities through the activation of inflammatory mediators and vascular endothelial cell injury, which play a critical role in inducing multiple organ dysfunction syndrome and subsequent death [1–4]. Thus, anticoagulant therapies are expected to be beneficial in the treatment of sepsis [5, 6]. Several anticoagulant therapies, such as recombinant human activated protein C, antithrombin, recombinant tissue factor pathway inhibitor, and recombinant human soluble thrombomodulin (rhTM), have already been evaluated as adjuvant therapy against sepsis [7–13]. However, the efficacy of anticoagulant therapies in sepsis remains a matter of dispute because of limited evidence that it improves clinical outcomes.

Although most previous studies of anticoagulants did not observe reduced mortality overall in patients with sepsis, some subgroup analyses suggest that anticoagulant therapies might be beneficial only in specific patients with sepsis. For example, the post hoc subgroup analysis of a large multinational randomised controlled trial (RCT) of antithrombin suggested that favourable treatment effects of antithrombin were observed only in patients with sepsis with predicted mortality between 30 % and 60 % according to the baseline Simplified Acute Physiology Score II score [14]. Additionally, antithrombin treatment was associated with a significant reduction in mortality only in patients suffering from sepsis-induced disseminated intravascular coagulation (DIC) and not in non-DIC patients [15]. We previously demonstrated significant association between recombinant human soluble thrombomodulin (rhTM) treatment and favourable mortality outcome only in patients with both sepsis-induced DIC and high risk of death according to baseline Acute Physiology and Chronic Health Evaluation (APACHE) II and Sequential Organ Failure Assessment (SOFA) scores [16].

We thus hypothesised that anticoagulant therapies might be effective only in patients with sepsis who are at high risk of death and have DIC, and might not be effective in other patients. This study aimed to analyse the association between anticoagulant therapy and outcomes in sepsis according to baseline DIC status and baseline disease severity.

Methods
Study population
This investigation was a post hoc subgroup analysis of a multicentre nationwide retrospective cohort study (the Japan Septic Disseminated Intravascular Coagulation (J-Septic DIC) registry) conducted in 42 intensive care units (ICUs) in Japan between January 2011 and December 2013 [17]. Patients were eligible for the registry if they had a known or suspected infection on the basis of clinical data and met the following criteria at the time of ICU admission: three or more signs of systemic inflammation and sepsis-induced dysfunction of at least one organ or system, and age ≥18 years. The exclusion criteria included the use of warfarin/acyetyl salicylic acid/thrombolytic therapy before study entry; history of fulminant hepatitis, decompensated liver cirrhosis, or other serious liver disorder; history of haematologic malignant disease; other conditions increasing the risk of bleeding; treatment with any chemotherapy at study entry; and patients with missing data for primary evaluation.

Participants were categorised into one of two groups: the anticoagulant group, comprising patients who underwent systemic administration at therapeutic doses of any anticoagulant such as antithrombin, rhTM, heparin/heparinoid or serine protease inhibitors, and the control group comprising patients who received no anticoagulant therapy. There was no predefined protocol on definite indications for anticoagulant therapy. Anticoagulant therapy in patients with sepsis fulfilling the criteria for DIC was applied at the discretion of the attending physician based on the treatment principles of each hospital. The standard dosage and duration of treatment for each anticoagulant agent used for sepsis-induced DIC in Japan are shown in Additional file 1: Table S1. No patients were administered recombinant human activated protein C because it had not been approved for the treatment of sepsis in Japan. Patients receiving prophylactic administration of low-dose heparin/heparinoid for venous thromboembolism were included in both groups.

This study followed the principles of the Declaration of Helsinki and was approved by the institutional review board of each participating hospital (Additional file 1: Table S2). Because of the anonymous and retrospective nature of this study, the board of each hospital waived the need for informed consent. This study was registered with the University Hospital Medical Information Network Clinical Trial Registry (UMIN-CTR ID: UMIN000012543).

Data collection
A case report form was developed on which the following information was recorded: age, sex, multiple illness severity scores on the day of ICU admission, source of ICU admission, pre-existing conditions, new organ dysfunction, primary source of infection, and concomitant therapies against sepsis. The severity of illness was evaluated at the time of ICU admission according to the APACHE II score and systemic inflammatory response syndrome score. Organ dysfunction, defined as a SOFA sub-score ≥2 for each organ, was assessed according to the SOFA score at the time of ICU admission. DIC was diagnosed on the basis of the criteria of the International Society on Thrombosis and Haemostasis (ISTH) and the Japanese Association for Acute Medicine (JAAM) at the time of ICU admission.
admission. Details of the scoring systems for the ISTH overt DIC [18, 19] and the JAAM DIC definitions [20] are summarised in Additional file 1: Table S3.

The primary outcome measure was all-cause in-hospital mortality. We also recorded as secondary outcomes any bleeding complications, including the occurrence of intracranial haemorrhage, transfusion requirements related to bleeding, and bleeding requiring surgical intervention.

Statistical analysis
The aim of this study was to identify a subset of patients with high benefit profiles for anticoagulant therapy against sepsis. Classification and regression trees for survival data (survival CART) were thus used to classify patients according to disease severity as determined by SOFA and APACHE II scores and age.

Due to the retrospective nature of the study, there were baseline imbalances between the two patient groups; therefore, an adjusted mortality analysis was performed using propensity scores [21, 22]. The propensity score for receiving anticoagulant therapy was calculated using multivariate logistic regression and included 32 independent variables comprising age, sex, disease severity, source of ICU admission, past medical history of severe conditions, new organ dysfunction, ICU characteristics, primary source of infection, causal microorganisms, anticoagulant therapy for indications other than DIC, and other therapeutic interventions (see Additional file 1: Table S4). The c statistic was 0.818. The Hosmer-Lemeshow chi-square value was 12.840 ($df = 8$), with a nonsignificant $p$ value of 0.117, which indicates that the model fit well.

Patients were stratified into quintiles according to their propensity scores. The overall association between treatment and mortality outcomes was assessed using a Cox regression model with strata defined by propensity score hazard ratio (HR) and estimated 95% confidence interval (CI). For secondary outcomes of bleeding complications, the odds ratio (OR) and associated 95% CI were estimated by logistic regression stratified by propensity score. Inverse probability-of-treatment weighting using the propensity score was also used to assess the robustness of the conclusions from the adjusted method, and no major significant differences between the methods were found.

Descriptive statistics were calculated as medians (interquartile range) or proportions, as appropriate. Univariate differences between groups were assessed using the Mann-Whitney $U$ test, Kruskal-Wallis test, chi-square test, or Fisher’s exact test. A $p$ value <0.05 indicated statistical significance. All statistical analyses were performed with IBM SPSS Statistics version 22.0 for Windows (SPSS Inc., Chicago, IL, USA), or R software package version 3.2.0 (R Development Core Team).

Results
Study population and stratification by survival CART
The patient flow diagram is shown in Fig. 1. During the study period, 3195 consecutive patients fulfilling the inclusion criteria were registered in the J-Septic DIC registry database. After excluding 532 patients who met at least one exclusion criterion, we analysed 2663 patients as the final study cohort. The anticoagulant group comprised 1247 patients and the control group comprised 1416 patients.

Survival CART analysis of SOFA scores revealed that the first split point at which to partition mortality risk for patients without anticoagulant therapy was a SOFA score of 13, and the second split points were SOFA scores of 8 and 18 for all subsets of patients (Fig. 2). Therefore, the associations between anticoagulant therapy and outcomes were estimated in these four subsets. Patients were also

---

**Fig. 1** Patient flow diagram. *J-Septic DIC* Japan Septic Disseminated Intravascular Coagulation, *SCCM/ACCP* Society of Critical Care Medicine/American College of Chest Physicians, *SOFA* Sequential Organ Failure Assessment, *APACHE* Acute Physiology and Chronic Health Evaluation
classified in the same manner according to APACHE II score and age.

**Baseline characteristics**

Baseline characteristics and therapeutic interventions of the overall study population are shown in Table 1. Although patient characteristics such as age and sex were similar between the anticoagulant and control groups, illness severity, as indicated by SOFA, APACHE II, and DIC scores, and the rate of new organ dysfunction showed significant differences between groups. The most common sites of underlying infection among all patients were the abdomen (33 %) and the lung (25 %), but these rates were not similar between treatment groups. The rate of concomitant therapeutic interventions against sepsis was also different between groups.

Additionally, baseline characteristics and therapeutic interventions in patients treated or not treated with anticoagulant in the specific subset according to baseline DIC status and SOFA score are shown in Table 2 and Additional file 1: Table S5, respectively. The anticoagulant and control groups of the DIC-positive subset were well balanced in age, sex, rate of new organ dysfunction, and primary source of infection, whereas in the DIC-negative subset, there were some differences between the two groups. Baseline severity of the coagulation disorder determined by JAAM DIC scores and the rate of concomitant therapeutic interventions were both significantly higher in the anticoagulant group relative to the control group in the two subsets with and without ISTH overt DIC.

**Mortality according to baseline DIC status**

Survival curves for the anticoagulant and control groups in the prediction model are shown in Fig. 3 according to covariates of propensity scores for subsets determined by DIC status diagnosed using both the ISTH overt DIC and JAAM DIC criteria. Significant associations between anticoagulant therapy and lower in-hospital mortality were observed only in the subsets of patients diagnosed with DIC (adjusted HR 0.609; 95 % CI 0.456, 0.814; \( p = 0.001 \) for the subset positive for ISTH overt DIC and adjusted HR 0.685; 95 % CI 0.559, 0.839; \( p <0.001 \) for the subset positive for JAAM DIC), whereas similar mortality rates were observed in the non-DIC subsets with anticoagulant therapy (adjusted HR 0.941; 95 % CI 0.773, 1.145; \( p = 0.543 \) for the subset negative for ISTH overt DIC and adjusted HR 1.104; 95 % CI 0.839, 1.453; \( p = 0.478 \) for the subset negative for JAAM DIC).

**Mortality according to baseline SOFA score**

Survival curves for the anticoagulant and control groups in the prediction model are shown in Fig. 4 according to covariates of propensity scores for subsets determined by baseline SOFA scores. Cox regression analysis suggested that anticoagulant therapy was significantly associated with reduced mortality but only in patients in the high-risk subset (SOFA \( \geq 13 \); adjusted HR 0.601; 95 % CI 0.451, 0.800; \( p <0.001 \)). In contrast, no association with survival was evident in the low-risk subset (SOFA \( \leq 7 \); adjusted HR 1.063; 95 % CI 0.716, 1.580; \( p = 0.761 \)) and moderate-risk subset (SOFA \( 8 \rightarrow 12 \); adjusted HR 0.927; 95 % CI 0.728, 1.181; \( p = 0.540 \)). The estimated survival rates in the very high-risk subset were similar in the treated and untreated groups (SOFA \( \geq 18 \); adjusted HR 0.915; 95 % CI 0.418, 2.003; \( p = 0.825 \)), but this analysis was not definitive because of the small sample sizes of the subsets.
Mortality according to other baseline characteristics

A similar tendency was observed in the analysis of subsets based on a number of other clinical measures of baseline illness severity (Fig. 5 and Additional file 1: Table S6). When the population was separated into subsets according to APACHE II scores, an insignificant

Table 1: Baseline characteristics of all patients treated or not treated with anticoagulants

| Patient characteristics | Overall (n = 2663) | Anticoagulant group (n = 1247) | Control group (n = 1416) | P value |
|-------------------------|-------------------|-----------------|-----------------|---------|
| Age in years            | 73 (63–81)        | 72 (62–80)      | 73 (63–81)      | 0.034   |
| Male sex                | 1576 (59 %)       | 716 (57 %)      | 860 (61 %)      | 0.089   |
| Illness severity        |                   |                 |                 |         |
| SIRS score              | 3 (2–4)           | 3 (2–4)         | 3 (2–4)         | 0.508   |
| SOFA score              | 9 (6–12)          | 10 (8–13)       | 8 (5–11)        | <0.001  |
| APACHE II score         | 22 (16–28)        | 23 (18–29)      | 21 (16–27)      | <0.001  |
| ISTH DIC score          | 3 (1–4)           | 4 (2–5)         | 2 (1–4)         | <0.001  |
| JAAM DIC score          | 4 (2–6)           | 5 (3–6)         | 3 (2–5)         | <0.001  |
| Source of ICU admission |                   |                 |                 | <0.001  |
| Emergency department    | 1256 (47 %)       | 527 (42 %)      | 729 (52 %)      | -       |
| Ward                    | 711 (27 %)        | 366 (29 %)      | 345 (24 %)      | -       |
| Other hospital          | 696 (26 %)        | 354 (28 %)      | 342 (24 %)      | -       |
| Pre-existing condition  |                   |                 |                 |         |
| Liver insufficiency     | 19 (1 %)          | 12 (1 %)        | 7 (1 %)         | 0.171   |
| Chronic heart failure   | 143 (5 %)         | 76 (6 %)        | 67 (5 %)        | 0.122   |
| Chronic respiratory disorder | 102 (4 %)   | 42 (3 %)        | 60 (4 %)        | 0.266   |
| Chronic haemodialysis   | 209 (8 %)         | 84 (7 %)        | 125 (9 %)       | 0.051   |
| Immunocompromised       | 280 (11 %)        | 130 (10 %)      | 150 (11 %)      | 0.899   |
| New organ dysfunction (SOFA sub-scores ≥2) |       |                 |                 |         |
| Respiratory             | 1792 (88 %)       | 851 (68 %)      | 941 (67 %)      | 0.341   |
| Cardiovascular          | 1761 (66 %)       | 934 (75 %)      | 827 (58 %)      | <0.001  |
| Renal                   | 1279 (48 %)       | 707 (57 %)      | 572 (40 %)      | <0.001  |
| Hepatic                 | 441 (17 %)        | 253 (20 %)      | 188 (13 %)      | <0.001  |
| Coagulation             | 957 (36 %)        | 591 (47 %)      | 366 (26 %)      | <0.001  |
| Primary source of infection |             |                 |                 | <0.001  |
| Abdomen                 | 881 (33 %)        | 460 (37 %)      | 421 (30 %)      | -       |
| Lung                    | 677 (25 %)        | 269 (22 %)      | 408 (29 %)      | -       |
| Urinary tract           | 456 (17 %)        | 221 (18 %)      | 235 (17 %)      | -       |
| Bone/soft tissue        | 309 (12 %)        | 146 (12 %)      | 163 (12 %)      | -       |
| Central nervous system  | 57 (2 %)          | 30 (2 %)        | 27 (2 %)        | -       |
| Other/unknown           | 283 (11 %)        | 121 (10 %)      | 162 (11 %)      | -       |
| Other therapeutic interventions |         |                 |                 |         |
| Immunoglobulin          | 800 (30 %)        | 590 (47 %)      | 210 (15 %)      | <0.001  |
| Low-dose steroid        | 624 (23 %)        | 401 (32 %)      | 223 (16 %)      | <0.001  |
| Renal replacement therapy | 830 (31 %)  | 566 (45 %)      | 264 (19 %)      | <0.001  |
| PMX-DHP                 | 574 (22 %)        | 410 (33 %)      | 164 (12 %)      | <0.001  |
| Surgical intervention   | 1153 (43 %)       | 617 (50 %)      | 536 (38 %)      | <0.001  |

Data are expressed as group medians (interquartile range) or proportion (%). SIRS Systemic Inflammatory Response Syndrome, SOFA Sequential Organ Failure Assessment, APACHE Acute Physiology and Chronic Health Evaluation, ISTH International Society on Thrombosis and Haemostasis, DIC disseminated intravascular coagulation, JAAM Japanese Association for Acute Medicine, ICU intensive care unit, PMX-DHP polymyxin B direct haemoperfusion
Table 2 Baseline characteristics of the patients with and without DIC diagnosed by ISTH overt DIC criteria treated or untreated with anticoagulants

|                                | Non-DIC (n = 2037) | DIC (n = 626) | P value | Non-DIC (n = 814) | DIC (n = 433) | P value | Non-DIC (n = 1223) | DIC (n = 193) | P value |
|--------------------------------|--------------------|---------------|---------|-------------------|---------------|---------|--------------------|---------------|---------|
| **Patient characteristics**    |                    |               |         |                   |               |         |                    |               |         |
| Age in years                   | 72 (63–80)         | 73 (63–81)    | 0.127   | 72 (61–80)        | 73 (63–82)    | 0.314   |                    |               |         |
| Male sex                       | 485 (60 %)         | 743 (61 %)    | 0.611   | 231 (53 %)        | 117 (61 %)    | 0.098   |                    |               |         |
| **Illness severity**           |                    |               |         |                   |               |         |                    |               |         |
| SIRS score                     | 3 (2–4)            | 3 (2–4)       | 0.522   | 3 (3–4)           | 3 (3–4)       | 0.078   |                    |               |         |
| SOFA score                     | 9 (7–12)           | 7 (5–10)      | <0.001  | 12 (9–14)         | 12 (9–15)     | 0.520   |                    |               |         |
| APACHE II score                | 23 (17–28)         | 20 (15–26)    | <0.001  | 25 (19–30)        | 24 (18–33)    | 0.342   |                    |               |         |
| ISTH DIC score                 | 3 (2–4)            | 2 (1–3)       | <0.001  | 6 (5–6)           | 6 (5–6)       | 0.411   |                    |               |         |
| JAAM DIC score                 | 4 (3–5)            | 2 (1–4)       | <0.001  | 7 (6–8)           | 6 (5–8)       | 0.004   |                    |               |         |
| **Source of ICU admission**    |                    |               |         |                   |               |         |                    |               | 0.395   |
| Emergency department           | 349 (43 %)         | 639 (52 %)    | -       | 178 (41 %)        | 90 (47 %)     | -       |                    |               |         |
| Ward                           | 233 (29 %)         | 294 (24 %)    | -       | 133 (31 %)        | 51 (26 %)     | -       |                    |               |         |
| Other hospital                 | 232 (29 %)         | 290 (24 %)    | -       | 122 (30 %)        | 52 (27 %)     | -       |                    |               |         |
| **Pre-existing condition**     |                    |               |         |                   |               |         |                    |               |         |
| Liver insufficiency            | 7 (0.9 %)          | 3 (0.2 %)     | 0.100   | 5 (1 %)           | 4 (2 %)       | 0.468   |                    |               |         |
| Chronic heart failure          | 49 (6 %)           | 60 (5 %)      | 0.315   | 27 (6 %)          | 7 (4 %)       | 0.251   |                    |               |         |
| Chronic respiratory disorder   | 31 (4 %)           | 50 (4 %)      | 0.817   | 11 (3 %)          | 10 (5 %)      | 0.097   |                    |               |         |
| Chronic haemodialysis          | 54 (7 %)           | 98 (8 %)      | 0.264   | 30 (7 %)          | 27 (14 %)     | 0.006   |                    |               |         |
| Immunocompromised              | 86 (11 %)          | 134 (11 %)    | 0.827   | 44 (10 %)         | 16 (8 %)      | 0.557   |                    |               |         |
| **New organ dysfunction (SOFA sub-scores ≥2)** | | | | | | | | | |
| Respiratory                    | 565 (69 %)         | 812 (66 %)    | 0.161   | 286 (66 %)        | 129 (67 %)    | 0.927   |                    |               |         |
| Cardiovascular                 | 605 (74 %)         | 681 (56 %)    | <0.001  | 329 (76 %)        | 146 (76 %)    | 0.920   |                    |               |         |
| Renal                          | 416 (51 %)         | 454 (37 %)    | <0.001  | 291 (67 %)        | 118 (61 %)    | 0.147   |                    |               |         |
| Hepatic                        | 114 (14 %)         | 136 (11 %)    | 0.054   | 139 (32 %)        | 52 (27 %)     | 0.222   |                    |               |         |
| Coagulation                    | 239 (29 %)         | 226 (19 %)    | <0.001  | 352 (81 %)        | 140 (73 %)    | 0.015   |                    |               |         |
| **Primary source of infection**|                    |               |         |                   |               |         |                    |               | 0.257   |
| Abdomen                        | 304 (37 %)         | 342 (28 %)    | -       | 156 (36 %)        | 79 (41 %)     | -       |                    |               |         |
| Lung                           | 205 (25 %)         | 383 (31 %)    | -       | 64 (15 %)         | 25 (13 %)     | -       |                    |               |         |
| Urinary tract                  | 113 (14 %)         | 199 (16 %)    | -       | 108 (25 %)        | 36 (19 %)     | -       |                    |               |         |
| Bone/soft tissue               | 102 (13 %)         | 145 (12 %)    | -       | 44 (10 %)         | 18 (9 %)      | -       |                    |               |         |
| Central nervous system         | 15 (2 %)           | 22 (2 %)      | -       | 15 (4 %)          | 5 (3 %)       | -       |                    |               |         |
| Other/unknown                  | 75 (9 %)           | 132 (11 %)    | -       | 46 (11 %)         | 30 (16 %)     | -       |                    |               |         |
| **Other therapeutic interventions** | | | | | | | | | |
| Immunoglobulin                 | 377 (46 %)         | 179 (15 %)    | <0.001  | 213 (49 %)        | 31 (16 %)     | <0.001  |                    |               |         |
| Low-dose steroid               | 248 (31 %)         | 184 (15 %)    | <0.001  | 153 (35 %)        | 39 (20 %)     | <0.001  |                    |               |         |
| Renal replacement therapy      | 351 (43 %)         | 204 (17 %)    | <0.001  | 215 (50 %)        | 60 (31 %)     | <0.001  |                    |               |         |
| PMX-DHP                        | 251 (31 %)         | 137 (11 %)    | <0.001  | 159 (37 %)        | 27 (14 %)     | <0.001  |                    |               |         |
| Surgical intervention          | 415 (51 %)         | 458 (37 %)    | <0.001  | 202 (47 %)        | 78 (40 %)     | 0.164   |                    |               |         |

Data are expressed as group medians (interquartile range) or proportion (%). DIC disseminated intravascular coagulation, ISTH International Society on Thrombosis and Haemostasis, SIRS Systemic Inflammatory Response Syndrome, SOFA Sequential Organ Failure Assessment, APACHE Acute Physiology and Chronic Health Evaluation, JAAM Japanese Association for Acute Medicine, ICU intensive care unit, PMX-DHP polymyxin B direct haemoperfusion.
A reduction in mortality associated with anticoagulant therapy was observed in the moderate-risk and high-risk subsets (APACHE II scores 20–30 and 36–43, respectively), whereas in the low-risk subset (APACHE II score ≤19), there was no difference between the anticoagulant and control groups. In terms of each organ dysfunction, associations between anticoagulant therapy and better outcome were observed only in the subset with organ dysfunction such as respiratory, cardiovascular, renal, and hepatic dysfunction, i.e. only in the population with greater illness severity.

**Adverse events**
Bleeding complications stratified by baseline SOFA score subsets are presented in Table 3. Rates of transfusion requirement related to bleeding tended to increase in the treated groups compared with those in the untreated groups in any SOFA subset, but the differences were not statistically significant. Other outcomes, such as occurrence of intracranial haemorrhage and bleeding requiring surgical intervention, were similar in the treated and untreated groups of any SOFA subset.

**Discussion**

**Summary of evidence**
Numerous large clinical trials of anticoagulant agents did not show a reduction in mortality among all patients with sepsis [8, 9, 11]; thus, it is important to identify specific subsets of patients with sepsis who can benefit from anticoagulant therapy. The present study represents the first attempt to evaluate the benefit profile of anticoagulant therapy in patients with sepsis. The current analyses provide evidence that anticoagulant therapies were associated with lower mortality in the DIC-positive subset, but no such association was evident in the DIC-negative subset. A similar benefit profile was observed in the analysis of the subsets stratified by SOFA score: a significant association between anticoagulant therapy and reduction in mortality was observed in a high-risk subset of patients with sepsis (SOFA score 13–17) but not in the low-risk to moderate-risk subsets (SOFA score ≤12). Furthermore, in patients with sepsis the association between anticoagulant therapy and better outcome was greater in patients with organ dysfunction than in those without organ dysfunction. Overall, the present analyses suggest that...
anticoagulant therapies may only be effective in sepsis among patients with DIC involving a high risk of death. Thus, future RCTs of anticoagulant therapy for sepsis should focus on specific populations, such as those with sepsis-induced DIC, multiple organ dysfunction, or very severe disease.

**Treatment effects according to baseline DIC status**

Our study showing a significant association between anticoagulant therapy and reduced mortality only in the DIC-positive subset agreed with the findings of many observational studies and post hoc subgroup analyses of RCTs [15, 23, 24]. It also showed that anticoagulant therapy is not associated with better outcome when it is administered to patients without DIC. These observations are explained by recent pathophysiological evidence on the innate immune response. Under certain circumstances, thrombosis is considered to play a major physiological role, termed “immunothrombosis”, in immune defence [25–27]. In the non-DIC subset of patients, anticoagulant therapy could have inhibited host-defensive thrombosis, which helps to capture and ensnare pathogens circulating in the blood, and therefore failed to improve mortality. However, in patients with DIC, impairment of the anticoagulant system leads to the overwhelming formation of fibrin and the uncontrolled activation of immunothrombosis, which play a critical role in inducing multiple organ dysfunction syndrome and subsequent death. Therefore, it is reasonable to assume that anticoagulant therapy to inhibit the over-activated coagulation cascade may be useful to improve outcomes in this subset of patients.

**Treatment effects according to baseline disease severity**

Our findings on the association between anticoagulant therapy and lower mortality according to disease severity or organ dysfunction agrees with those of many previous studies including a large multicentre RCT of activated protein C or antithrombin [7, 14, 28]. Additionally, our previous meta-analysis of the risk and efficacy of rhTM in sepsis suggests that its efficacy would increase as the risk of death increased [29].

Why were the effects of anticoagulant therapies in this study more evident only when they targeted severely ill patients? One possible reason is that patients who are severely ill are likely to present simultaneously with DIC, which is related to immunothrombosis. Second, differences between groups are likely to be statistically significant if the control event rate is high. Third, anticoagulants such as antithrombin and rhTM have specific anti-inflammatory activities unrelated to anticoagulant activity [30–32], and these anti-inflammatory effects might be clinically evident only in the severely ill patients.

**Adverse events**

Bleeding was the most significant adverse event associated with anticoagulant administration. Although the differences
were not statistically significant, there was a consistent tendency for bleeding-related transfusions to increase in all of the severity subsets (13–27 % in the anticoagulant group vs. 6–10 % in the control group). The decision to use an anticoagulant depends on the balance between efficacy and the safety of the intervention. Our results showed that anticoagulant therapy may only be useful in the sepsis subset with severe disease because of its beneficial effects on mortality and the relatively low risk of bleeding complications. In contrast, anticoagulant therapy in the overall sepsis population including the low-risk subset should not be recommended because of the risk of bleeding complications and lack of survival benefit.

**Limitations**

We acknowledge several limitations of our study. First, it is a non-randomised cohort study and hence suffers from potential selection and ascertainment bias. The indications for treatment and methodology for the treatment intervention being examined were not standardised. The baseline characteristics and intensity of ICU treatments other than anticoagulant therapies were different between the two groups. To cope with these imbalances caused by non-randomisation, we developed a propensity score approach that forces the analysts to explicitly focus on these biases.

Second, the registry data used in the study were retrospectively collected and did not capture detailed
information that may be considered as confounding, such as the timing or duration of anticoagulant therapies. We are not confident that biased estimation of the effects can be completely excluded despite robust adjustment with propensity scores.

Third, the present multicentre study did not focus on the treatment effects of specific anticoagulants. Thus, the knowledge obtained from the present study might be inadequate to influence decision making in clinical settings. To verify our hypothesis, we assumed that several of the anticoagulant agents displayed similar effects against sepsis, even though these agents have unique anticoagulant/antiinflammatory mechanisms and pharmacological features. Also, low-dose anticoagulants as prophylaxis against venous thromboembolism were included in both groups. The combination of these three major limitations might cause multiple unmeasured confounders to account for the differences in outcome observed in this study.

Finally, because this study involves subgroup analysis, we cannot deny the potential of accidental false-positive results. The study is also prone to false-negative results due to inadequate power with which to uncover differences in treatment effect, even in the presence of true treatment-effect modification. Further multicentre prospective randomised trials are therefore required to specifically evaluate efficacy and safety.

**Conclusions**

Our post hoc subgroup analysis using the multicentre nationwide J-Septic DIC registry in Japan demonstrated an association between anticoagulant therapy and lower mortality only in specific patients with sepsis, who are severely ill and have multiple organ dysfunction, or DIC. Thus, future RCTs of anticoagulant therapy for sepsis should focus on such specific patient populations.

**Key messages**

- Patients who will highly benefit from anticoagulant therapy against sepsis require identification
- Effects of anticoagulant therapy were evaluated by baseline disseminated intravascular coagulation status and by stratifying disease severity subsets
- Significant associations between anticoagulant therapy and survival were shown only in specific subsets of sepsis-induced disseminated intravascular coagulation or very severe disease
- Future randomised controlled trials of anticoagulant therapy for sepsis should focus on such specific patient populations

**Additional file**

[Online supplemental data](docx:63kb)

**Abbreviations**

APACHE, Acute Physiology And Chronic Health Evaluation; CI, confidence interval; DIC, disseminated intravascular coagulation; HR, hazard ratio; ICUs, intensive care units; ISTH, International Society on Thrombosis and Haemostasis; JAAM, Japanese Association for Acute Medicine; J-septic DIC, Japan Septic Disseminated Intravascular Coagulation; OR, odds ratio; RCT, randomised controlled trial; rhTM, recombinant human soluble thrombomodulin; SOFA, Sequential Organ Failure Assessment; survival CART, classification and regression trees for survival data
Acknowledgements

We wish to express our gratitude to all of the J-Septic DIC study contributors: Shinjiro Saito and Shigehiko Uchino (Jikei University School of Medicine), Yusuke Izuka and Wataru Matsunaga (Aichi Medical University Saitama Medical Center), Kohei Takimoto (Osaka University Graduate School of Medicine), Toshikazu Mayumi and Hideaki Ariai (University of Occupational and Environmental Health), Takeo Azuhata (Nihon University School of Medicine), Fumihito Ito (Ohta General Hospital Foundation Ohta Nishinhoku Hospital), Shodai Yoshishiro (J A Hiroshima General Hospital), Hayakawa Katsura (Saitama Red Cross Hospital), Tsuyoshi Nakashima (Wakayama Medical University), Takayuki Ogura (Japan Red Cross Maebashi Hospital), Eichiro Noda (Kyushu University Hospital), Yoshishiko Nakamura (Fukuoka University Hospital), Ryosuke Sekine (Ibaraki Prefectural Central Hospital), Motohiro Sekino (Nagasaki University Hospital), Keiko Ueno (Tokyo Medical University Hachioji Medical Center), Yuji Okuda (Kyoto First Red Cross Hospital), Masayuki Watanabe (Saiseikai Yokohamashi Tobu Hospital), Akihito Tampo (Asahikawa Medical University), Nobuyuki Saito (Nippon Medical School Chiba Hokusou Hospital), Yuya Kita (Nameda Medical Center), Iwao Kobayashi (Asahikawa Red Cross Hospital), Yurioka Kondo (Graduate School of Medicine, University of the Ryukyus), Sho Nachi (Gifu University Hospital), Tomu Mikale (Saga University Hospital), Hiroshi Takahashi (Steel Memorial Muronan Hospital), Shuhei Takuji (Sapporo City General Hospital), Kensei Umakoshi (Ehime University Hospital), Takafumi Todaka (Tomishiro Central Hospital), Hiroshi Kodaira (Akashi City Hospital), Kohichi Andoh (Sendai City Hospital), Takehiro Kaizai (Hakodate Municipal Hospital), Yoshitaka Iwashita (Mie University Hospital), Masato Murata (Gunma University), Masahiro Yamane (KRR Sapporo Red Cross Medical Center), Kazuhiro Shiga (Seirei Mikatahara general hospital), and Naoto Hori (Hyogo College of Medicine).

Authors’ contributions

KY conceived and designed this study, contributed to acquisition, analysis, and interpretation of the data, and was responsible for drafting, editing, and submission of the manuscript. YU contributed to interpretation of the data and drafting of the manuscript. MH, DK, and MS designed this study and contributed to data acquisition and revision of the manuscript for important intellectual content. HT and YY contributed to data acquisition and revision of the manuscript for important intellectual content. The authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Author details

1. Department of Emergency and Critical Care, Osaka General Medical Center, 3-1-56 Bandai-Higashi, Sumiyoshi-ku, Osaka 558-8558, Japan. 2. Department of Traumatology and Acute Critical Medicine, Osaka University Graduate School of Medicine, 2-15 Yamadakcho, Suita, Osaka 565-0871, Japan. 3. Emergency and Critical Care Center, Hokkaido University Hospital, Kita 15 Nishi 7 Kitaku, Sapporo, Hokkaido 060-8638, Japan. 4. Division of Emergency and Critical Care Medicine, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan. 5. Department of Anesthesiology and Critical Care Medicine, Jichi Medical University Saitama Medical Center, 1-847 Amanumo-cho, Omiya-ku, Saitama 330-8503, Japan. 6. Office of Biostatistics and Data Management, National Cerebral and Cardiovascular Center, 5-7-1 Fujishiriodai, Suita, Osaka 565-8565, Japan.

Received: 24 February 2016 Accepted: 20 July 2016
Published online: 29 July 2016

References

1. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013;369:840–51.
2. Esmor CT. The interactions between inflammation and coagulation. Br J Haematol. 2005;131:417–30.
3. Levi M, Schultz M, van der Poll T. Sepsis and thrombosis. Semin Thromb Hemost. 2013;39:559–66.
4. Ogura H, Gando S, Iba T, Eguchi Y, Ohtomo Y, Okamoto K, et al. SIRS-associated coagulopathy and organ dysfunction in critically ill patients with thrombocytopenia. Shock. 2007;28:411–7.
5. Fourrier F. Severe sepsis, coagulation, and fibrinolysis: dead end or one way? Crit Care Med. 2012;40:704–8.
6. Iba T, Nagaoka I, Boulant M. The anticoagulant therapy for sepsis-associated disseminated intravascular coagulation. Thromb Res. 2013;131:583–9.
7. Bernard GR, Vincent JL, Laterre PF, LaRossa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699–709.
8. Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med. 2006;356:255–64.
9. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA. 2003;290:28–47.
10. Gando S, Saito D, Ishikura H, Uyama M, Otomo Y, Oda S, et al. A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Crit Care Med. 2013;41:2069–79.
11. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, et al. Efficacy and safety of tafinocitin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003;290:238–47.
12. Aikawa N, Shimazaki S, Yamamoto Y, Saito H, Maruyama I, Ohno R, et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock. 2011;35:349–54.
13. Vincent JL, Ramesh MK, Ernest D, LaRosa SP, Pachl J, Aikawa N, et al. A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin. ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med. 2013;41:2069–79.
14. Wiedermann CJ, Hoffmann JN, Juers M, Ostermann H, Keimast J, Briel et al. High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Crit Care Med. 2006;34:285–92.
15. Keimast J, Juers M, Wiedermann CJ, Hoffmann JN, Ostermann H, Strauss R, et al. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost. 2006;490–7.
16. Yoshimura J, Yamakawa K, Ogura H, Umemura Y, Takahashi H, Morikawa M, et al. Benefit profile of recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis. Crit Care. 2015;19:78.
17. Hayakawa M, Yamakawa K, Saito S, Uchino S, Kudo D, Izuka Y, et al. Recombinant human soluble thrombomodulin and mortality in sepsis-induced disseminated intravascular coagulation. A multicentre retrospective study. Thromb Haemost. 2016;115:156–77.
18. Taylor JR, Toh CH, Hoos WK, Wada H, Levi M. Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86:327–30.
19. Gando S, Saito D, Ogura H, Mayumi T, Koski K, Ikeda T, et al. Natural history of disseminated intravascular coagulation diagnosed based on the newly established diagnostic criteria for critically ill patients: results of a multicenter, prospective survey. Crit Care Med. 2008;36:143–50.
20. Gando S, Iba T, Eguchi Y, Ohtomo Y, Okamoto K, Koski K, et al. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med. 2006;34:625–31.
21. D’Agostino Jr RB, D’Agostino Sr RB. Estimating treatment effects using observational data. JAMA. 2007;297:314–6.
22. Gayet E, Pinacho R, Resche-Rigon M, Mebazaa A, Mary JY, Porcher R. Propensity scores in intensive care and anaesthesiology literature: a systematic review. Intensive Care Med. 2010;36:1993–2003.
23. Dhainaut JF, Yan SB, Joyce DE, Petrov V, Basson B, Brandt JT, et al. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost. 2001;86:3127–30.
24. Gando S, Yamaoka K, Saito D, Ogura H, Mayumi T, Koski K, Ikeda T, et al. Natural history of disseminated intravascular coagulation diagnosed based on the newly established diagnostic criteria for critically ill patients: results of a multicenter, prospective survey. Crit Care Med. 2008;36:143–50.
25. Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol. 2013;13:34–45.
26. van der Poll T, Herwald H. The coagulation system and its function in early immune defense. Thromb Haemost. 2014;112:640–8.
27. Ito T. PAMPs and DAMPs as triggers for DIC. J Intensive Care. 2014;2:67.
28. Dhainaut JF, Laterre PF, Janes JM, Bernard GR, Artigas A, Bakker J, et al. Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial. Intensive Care Med. 2003;29:894–903.
29. Yamakawa K, Aihara M, Ogura H, Yuhara H, Hamasaki T, Shimazu T. Recombinant human soluble thrombomodulin in severe sepsis: a systematic review and meta-analysis. J Thromb Haemost. 2015;13:508–19.
30. Levy JH, Sniecinski RM, Welsby I, Levi M. Antithrombin: anti-inflammatory properties and clinical applications. Thromb Haemost. 2016;115(4):712–28.
31. Levi M, Van Der Poll T. Thrombomodulin in sepsis. Minerva Anestesiolog. 2013;79:294–8.
32. Ito T, Kakihana Y, Maruyama I. Thrombomodulin as an intravascular safeguard against inflammatory and thrombotic diseases. Expert Opin Ther Targets. 2015;11:1–8.